CONCUR: Subgroup analysis of OS
*Unstratified Cox regression model
Asia (other than China)
No anti-VEGF and no anti-EGFR
Subgroup
SEX
Male
Female
AGE
<65 years
≥65 years
METASTATIC SITES
Single
Multiple
FIRST mCRC DIAGNOSIS TO RANDOMIZATION
<18 months
≥18 months
NUMBER OF PRIOR TREATMENT LINES
≤3
>3
NUMBER OF PRIOR TREATMENT LINES
ON OR AFTER METASTATIC DISEASE
≤3
>3
BASELINE
KRAS
MUTATION STATUS
Mutant
Wild type
Unknown
BASELINE ECOG PERFORMANCE STATUS
0
1
BASELINE
BRAF
MUTATION STATUS
Mutant
Wild type
Unknown
Anti-VEGF and no anti-EGFR
Anti-EGFR and no anti-VEGF
Both anti-VEGF and anti-EGFR
PRIOR TARGETED THERAPY
Anti-VEGF, or anti-EGFR, or both
REGION
China (mainland China, Hong Kong, Taiwan)
0.0 0.5 1.0 1.5 2.0 2.5
N
118
86
153
51
43
161
85
119
96
108
125
79
64
79
61
50
154
1
42
161
172
32
0.647 (0.411–1.017)
0.478 (0.294–0.777)
0.586 (0.408–0.843)
0.613 (0.275–1.368)
0.364 (0.166–0.798)
0.598 (0.417–0.860)
0.518 (0.316–0.850)
0.600 (0.385–0.933)
0.629 (0.388–1.019)
0.514 (0.330–0.800)
0.648 (0.425–0.986)
0.459 (0.273–0.774)
0.647 (0.363–1.153)
0.589 (0.343–1.011)
0.416 (0.228–0.758)
0.613 (0.300–1.253)
0.564 (0.390–0.814)
Not assessable
0.436 (0.210–0.906)
0.565 (0.392–0.814)
0.569 (0.400–0.808)
0.487 (0.196–1.212)
Favors placebo
Favors regorafenib
0.359 (0.215–0.601)
84
120
0.987 (0.482–2.025)
45
0.747 (0.488–1.145)
0.484 (0.217–1.081)
0.719 (0.340–1.523)
39
36
Hazard ratio (95% confidence interval)*
